Astria Therapeutics ATXS

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.23 (-3.58%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Astria Therapeutics (ATXS)
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $6.19

  • Market Cap

    $349.33 Million

  • Price-Earnings Ratio

    -14.74

  • Total Outstanding Shares

    56.43 Million Shares

  • Total Employees

    59

  • Dividend

    No dividend

  • IPO Date

    June 25, 2015

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    22 boston wharf road, Boston, MA, 02210

  • Homepage

    https://www.astriatx.com

Historical Stock Splits

If you bought 55.607 shares of ATXS before March 18, 2004, you'd have 1 share today.
Execution DateSplit Amount
August 20, 20211-for-6 (Reverse Split)
December 31, 20181-for-10 (Reverse Split)
March 29, 2005104-for-100
March 18, 2004103.75-for-100

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-6.48 Million
Net Cash Flow From Operating Activities, Continuing$-27.96 Million
Net Cash Flow From Investing Activities, Continuing$6.19 Million
Net Cash Flow From Financing Activities, Continuing$15.30 Million
Net Cash Flow From Financing Activities$15.30 Million
Net Cash Flow From Investing Activities$6.19 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Income/Loss$-24.53 Million
Net Income/Loss Attributable To Noncontrolling Interest$0
Basic Average Shares$57.82 Million
Diluted Average Shares$57.82 Million
Diluted Earnings Per Share$-0.42
Income/Loss From Continuing Operations Before Tax$-24.53 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss$-24.16 Million
Other Comprehensive Income/Loss Attributable To Parent$376,000
Comprehensive Income/Loss Attributable To Parent$-24.16 Million
Other Comprehensive Income/Loss$-24.16 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Equity Attributable To Parent$341.65 Million
Noncurrent Liabilities$4.26 Million
Accounts Payable$1.28 Million
Liabilities$19.98 Million
Wages$3.62 Million
Noncurrent Assets$9.78 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ATXS from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.